Aggarwal 2010.

Methods	Randomized, double‐blind, placebo‐controlled
Participants	United States and Canada N = 84 (lithium: 40, placebo: 44) Mean age 58.3 years (lithium), 55.5 years (placebo) Gender distribution, male (%): 75% (lithium), 55% (placebo) Family history of ALS: 8% (lithium), 2% (placebo)
Interventions	Lithium or placebo Lithium titrated to achieve serum concentration in the range of 0.4 to 0.8 mEq/l
Outcomes	Primary: time to event, defined as a decrease of at least 6 points from baseline on ALSFRS‐R or death Secondary: changes in the ALSRFS‐R, slow vital capacity, ALSSQOL and QIDS‐SR16
Notes	Support from the National Institute of Neurological Disorders and Stroke, the ALS Association and the ALS Society of Canada